My Companies
Notification
Account
Log Out
Login
Management guided FY27 consolidated revenue of at least ₹1,550 crore and PAT of at least ₹178 crore (11.4% margin), with FY28 commercialisation of sickle-cell testing and medical devices. It proposed an energy demerger, affordable CAR-T centres, UK/Swiss subsidiaries, two oncology hospitals and 50 dialysis centres by March 2027.
Lords Mark Industries Promoter Sells 2.43 Percent Stake Via Open Market
Lords Mark Industries Enters ARKALL Collaboration Targeting US$100 Million Export Revenue
Lord's Mark Receives India's First Biomescan SaMD Manufacturing Licence
Lord's Mark Industries Approves In-Principle MPS Plan With OFS And Rights Issue
Lords Mark Industries Commissions Vasai IVD Facility Two Months Early